Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

-
April 26, 2018
InDex Pharmaceuticals

Annual General Meeting 2018

Annual General Meeting in InDex Pharmaceuticals Holding AB will be held on May 24, 2018 at 5:00 p.m. (CET) at the company´s premises, Tomtebodavägen 23a in Stockholm, Sweden. Registration for the meeting will begin at 4:30 p.m.

Annual General Meeting 2018

Annual General Meeting in InDex Pharmaceuticals Holding AB will be held on May 24, 2018 at 5:00 p.m. (CET) at the company´s premises, Tomtebodavägen 23a in Stockholm, Sweden. Registration for the meeting will begin at 4:30 p.m.

Annual General Meeting in InDex Pharmaceuticals Holding AB will be held on May 24, 2018 at 5:00 p.m. (CET) at the company´s premises, Tomtebodavägen 23a in Stockholm, Sweden. Registration for the meeting will begin at 4:30 p.m.

Shareholders who wish to attend the Annual General Meeting must be recorded in the share register maintained by Euroclear Sweden AB on May 18, 2018, and give notice of attendance to the company by e-mail to annika.lindmark@indexpharma.com or under address: InDex Pharmaceuticals Holding AB, Tomtebodavägen 23a, 171 77 Stockholm, no later than May 18, 2018.

Documents

Last updated:
April 26, 2018

InDex Pharmaceuticals

InDex Pharmaceuticals lead drug candidate is cobitolimod – a new type of drug that can help patients back to a normal life. InDex has also developed a platform of patent protected substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.

Click here to read more about us!
Get in touch with us!
Visit us

InDex Pharmaceuticals Holding AB (publ)
Tomtebodavägen 23a
SE-171 77 Stockholm, Sweden

Send us mail

Annual General Meeting in InDex Pharmaceuticals Holding AB will be held on May 24, 2018 at 5:00 p.m. (CET) at the company´s premises, Tomtebodavägen 23a in Stockholm, Sweden. Registration for the meeting will begin at 4:30 p.m.

Shareholders who wish to attend the Annual General Meeting must be recorded in the share register maintained by Euroclear Sweden AB on May 18, 2018, and give notice of attendance to the company by e-mail to annika.lindmark@indexpharma.com or under address: InDex Pharmaceuticals Holding AB, Tomtebodavägen 23a, 171 77 Stockholm, no later than May 18, 2018.

Documents

Last updated:
April 26, 2018

InDex Pharmaceuticals

InDex Pharmaceuticals lead drug candidate is cobitolimod – a new type of drug that can help patients back to a normal life. InDex has also developed a platform of patent protected substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.

Click here to read more about us!
Get in touch with us!
Visit us

InDex Pharmaceuticals Holding AB (publ)
Tomtebodavägen 23a
SE-171 77 Stockholm, Sweden

Send us mail